» Articles » PMID: 32393531

Preferred and Actual Place of Death in Haematological Malignancies: a Report from the UK Haematological Malignancy Research Network

Overview
Date 2020 May 13
PMID 32393531
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Hospital death is comparatively common in people with haematological cancers, but little is known about patient preferences. This study investigated actual and preferred place of death, concurrence between these and characteristics of preferred place discussions.

Methods: Set within a population-based haematological malignancy patient cohort, adults (≥18 years) diagnosed 2004-2012 who died 2011-2012 were included (n=963). Data were obtained via routine linkages (date, place and cause of death) and abstraction of hospital records (diagnosis, demographics, preferred place discussions). Logistic regression investigated associations between patient and clinical factors and place of death, and factors associated with the likelihood of having a preferred place discussion.

Results: Of 892 patients (92.6%) alive 2 weeks after diagnosis, 58.0% subsequently died in hospital (home, 20.0%; care home, 11.9%; hospice, 10.2%). A preferred place discussion was documented for 453 patients (50.8%). Discussions were more likely in women (p=0.003), those referred to specialist palliative care (p0.001), and where cause of death was haematological cancer (p0.001); and less likely in those living in deprived areas (p=0.005). Patients with a discussion were significantly (p<0.05) less likely to die in hospital. Last recorded preferences were: home (40.6%), hospice (18.1%), hospital (17.7%) and care home (14.1%); two-thirds died in their final preferred place. Multiple discussions occurred for 58.3% of the 453, with preferences varying by proximity to death and participants in the discussion.

Conclusion: Challenges remain in ensuring that patients are supported to have meaningful end-of-life discussions, with healthcare services that are able to respond to changing decisions over time.

Citing Articles

Challenges in hospice and end-of-life care in the transfusion-dependent patient.

Rodenbach R, Caprio T, Loh K Hematology Am Soc Hematol Educ Program. 2024; 2024(1):340-347.

PMID: 39644067 PMC: 11665515. DOI: 10.1182/hematology.2024000560.


Quality of end-of-life care in patients with hematological malignancies: potential role of palliative care.

Allende-Perez S, Valdes-Flores M, Rodriguez-Mayoral O, Cruz-Sanchez J, Pena-Nieves A, Herrera-Guerrero M Support Care Cancer. 2024; 32(12):831.

PMID: 39607499 DOI: 10.1007/s00520-024-09047-4.


Characteristics of cancer patients dying at home during the COVID-19 pandemic: A study based on vital statistics from 2015 to 2022 in Japan.

Sun Y, Masuda R, Taniguchi Y, Iwagami M, Sakata N, Yoshie S J Gen Fam Med. 2024; 25(6):358-365.

PMID: 39554288 PMC: 11565075. DOI: 10.1002/jgf2.724.


Place of Death for Adults Receiving Specialist Palliative Care in Their Last 3 Months of Life: Factors Associated With Preferred Place, Actual Place, and Place of Death Congruence.

Smith S, Brick A, Johnston B, Ryan K, McQuillan R, OHara S J Palliat Care. 2024; 39(3):184-193.

PMID: 38404130 PMC: 11097611. DOI: 10.1177/08258597241231042.


End-of-Life Care of Acute Myeloid Leukemia Compared with Aggressive lymphoma in Patients Who Are Eligible for Intensive Chemotherapy: An Observational Study in a Japanese Community Hospital.

Kokaji M, Imoto N, Watanabe M, Suzuki Y, Fujiwara S, Ito R Palliat Med Rep. 2023; 4(1):71-78.

PMID: 36960234 PMC: 10029750. DOI: 10.1089/pmr.2022.0056.


References
1.
Smith A, Howell D, Crouch S, Painter D, Blase J, Wang H . Cohort Profile: The Haematological Malignancy Research Network (HMRN): a UK population-based patient cohort. Int J Epidemiol. 2018; 47(3):700-700g. PMC: 6005016. DOI: 10.1093/ije/dyy044. View

2.
Woodman C, Baillie J, Sivell S . The preferences and perspectives of family caregivers towards place of care for their relatives at the end-of-life. A systematic review and thematic synthesis of the qualitative evidence. BMJ Support Palliat Care. 2015; 6(4):418-429. PMC: 5256384. DOI: 10.1136/bmjspcare-2014-000794. View

3.
Gomes B, Calanzani N, Gysels M, Hall S, Higginson I . Heterogeneity and changes in preferences for dying at home: a systematic review. BMC Palliat Care. 2013; 12:7. PMC: 3623898. DOI: 10.1186/1472-684X-12-7. View

4.
Webb J, LeBlanc T, El-Jawahri A . Integration of Palliative Care into Acute Myeloid Leukemia Care. Semin Oncol Nurs. 2019; 35(6):150959. DOI: 10.1016/j.soncn.2019.150959. View

5.
McCaughan D, Roman E, Smith A, Garry A, Johnson M, Patmore R . Determinants of hospital death in haematological cancers: findings from a qualitative study. BMJ Support Palliat Care. 2017; 8(1):78-86. PMC: 5867428. DOI: 10.1136/bmjspcare-2016-001289. View